Araclon vaccine appears to slow Alzheimer's in exploratory phase 2 analysis, spurring review of next steps

Araclon Biotech has provided early evidence that its Alzheimer’s disease vaccine is effective, linking the candidate to a 38% slowdown in disease progression compared to placebo in an exploratory analysis of phase 2 data.